Description: SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.
Home Page: www.sonnetbio.com
SONN Technical Analysis
100 Overlook Center
Princeton,
NJ
08540
United States
Phone:
609-375-2227
Officers
| Name | Title |
|---|---|
| Dr. Pankaj Mohan Ph.D. | Founder, Chairman. CEO & Pres |
| Dr. John K. Cini Ph.D. | Chief Scientific Officer & Co-Founder |
| Mr. Jay Cross | Chief Financial Officer |
| Ms. Susan Dexter | Chief Technical Officer |
| Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer |
| Mr. Manuel Dafonseca | Head of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.454 |
| Price-to-Sales TTM: | 9.0917 |
| IPO Date: | 2006-10-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |